Lastly, IL-22BP is a natural inhibitor of IL-22, having more than a 20-fold higher affinity for IL-22 than the cell surface receptor chain IL-22R1 (56), thus playing a pathogenic role in inflammatory bowel disease (IBD) (57) and multiple sclerosis (58) patients. Here, IL22RA2 is linked to inflammatory bowel disease.